ARKG bets on companies revolutionizing healthcare through gene editing, molecular diagnostics, and targeted therapeutics. This isn't your typical healthcare fund — it's concentrated in bleeding-edge biotech names that could either transform medicine or flame out spectacularly.
How It Works
ARK's analysts actively pick 30-50 stocks they believe will benefit from the genomic revolution, with positions sized by conviction rather than market cap. The fund rebalances based on fundamental changes in thesis, not calendar dates, and isn't afraid to hold 5-10% positions in single names. Heavy emphasis on CRISPR companies, liquid biopsy developers, and AI-driven drug discovery platforms.
Key Features
- Pure-play genomics exposure you can't replicate with biotech indices
- Active management by dedicated biotech analysts, not generalist PMs
- Willing to hold pre-revenue companies traditional funds won't touch
Risks
- Clinical trial failures can crater individual holdings 50-80% overnight
- Regulatory delays or safety concerns could freeze entire gene therapy sector
- Many holdings burn cash and need capital markets access to survive
Who Should Own This
Best for investors who understand biotech cycles and can stomach watching positions drop 30% on trial data. This is a satellite holding for true believers in genomic medicine, not a core healthcare allocation. If you need to Google what CRISPR is, you probably shouldn't own this.